Skip Navigation LinksTBCB-CA-Objectives-Targets-2025-2029

Tuberculosis control branch

California Tuberculosis Prevention and Control Objectives and Targets 2025-2029, by Strategy Areaā€‹

Objectives in regular font are NTIP indicators. Objectives in italics are California (non-NTIP) indicators.

Strategy 1: Diagnosis and treatment of persons with TB disease

ā€‹California Targets

ā€‹Objective

ā€‹2025

ā€‹2026

ā€‹ā€‹2027

ā€‹2028

ā€‹2029

1.1a     TB Case Rate

4.7

4.3

3.9

3.6

3.2

1.1b     US-Born Case Rateā€‹

1.0

0.9

0.7

0.6

0.5

1.1c     Non US-Born Case Rateā€‹

15.1

14.4

13.6

12.8

12.0

1.1d     African American Case Rate

1.6

1.2

0.ā€‹ā€‹8

0.5

0.1

1.1e     Pediatric Case Rate

0.9

0.7

0.5

0.3

0.1

1.1f     Asian Case Rate

15.9

15.4

14.8

14.3

13.7

1.1g     Hispanic/Latinx Case Rate

4.5

4.1

3.7

3.2

2.8

1.2     Known HIV Status

92%

94%

95%

97%

98%

1.3     Drug Susceptibility Result

96%

96%

97%

98%

98%

1.4     Sputum Culture Reported

93%

94%

95%

95%

96%

1.5     ā€‹Recommended Initial Therapy

94%

94%

95%

96%

97%

1.6       Treatment Initiation

91%

92%

93%

94%

94%

1.7       Sputum Culture Conversion

75%

76%

77%

78%

79%

1.8       Completion of Therapy

89%

89%

90%

90%

91%

1.9a    Nucleic Acid Amplification Test Used ā€“ Smear-Positive TB

73%

76%

80%

84%

88%

1.9b    Nucleic Acid Amplification Test Used ā€“ Smear-Negative TB

47%

51%

54%

58%

61%

1.10    Self-Administered Therapy

1.3%

1.2%

1.2%

1.1%

1.1%

1.11    Deaths with TB

8.9%

8.0%

7.1%

6.2%

5.3%

Strategy 2: Conduct contact investigationā€‹s fā€‹or infectious TB cases

California Targets

ā€‹Objective

ā€‹2025

ā€‹2026

ā€‹2027

ā€‹2028

ā€‹ā€‹2029

2.1      Contact Elicitation*

92%ā€‹ā€‹ā€‹

94%ā€‹

95%

97%

98%

2.2      Contact Examination*

82%

83%

84%

86%

87%

2.3      Contact LTBI Treatment Initiation*

78%

80%

82%

85%

87%

2.4      Contact LTBI Treatment Completion (of those starting treatment)*

82%

85%

87%

90%

93%

2.4a    Contact LTBI Treatment Completion (of those with LTBI)**

65%

69%

74%

79%

83%

Strategy 3: Test and treat populations at higher risk for TB and LTBIā€‹

California Targets

ā€‹Objective

ā€‹2025
ā€‹2026
ā€‹2027
ā€‹2028
ā€‹ā€‹2029

3.1      Immigrant/Refugee Evaluation Initiation within 30 Days

30%

37%

44%

51%

58%

3.2      Immigrant/Refugee Evaluation Completion within 120 Days

33%

37%

41%

45%

48%

3.2a    Immigrant/Refugee Evaluation Completion Ever

54%

59%

65%

70%

75%

3.3      Immigrant/Refugee LTBI Treatment Initiation

73%

75%

77%

79%

81%

3.4      Immigrant/Refugee LTBI Treatment Completion

84%

86%

88%

90%

92%

3.5      Persons in High Risk Group Tested for LTBI

TBD

TBD

TBD

TBD

TBD

3.6      Persons in High Risk Group Completing LTBI Treatment

TBD

TBD

TBD

TBD

TBD

Strategy 5: Surveillance

ā€‹California Targets

ā€‹Objective

ā€‹2025
ā€‹2026
ā€‹2027
ā€‹2028
ā€‹ā€‹2029

5.1      Data Reporting ā€“ RVCT

99%

99%

99%

99%

99%

5.2      Universal Genotyping

96%

96%

97%

97%

98%

5.3      Data Reportiā€‹ā€‹ng ā€“ ARPE

89%

89%

89%

89%

89%

5.4      Data Reporting ā€“ EDN

78%

82%

85%

89%

93%

Strategy 7: Laborā€‹atory Strengthening

ā€‹California Targets

ā€‹Objective

ā€‹2025

ā€‹2026

ā€‹2027

ā€‹2028

ā€‹ā€‹2029

7.1      Laboratory Turnaround Time ā€“ Culture

52%

53%

54%

55%

55%

7.2      Laboratory Turnaround Time ā€“ NAATā€‹ā€‹

89%

91%

92%

93%

94%

* Contacts to smear-positive TB; **Contacts to smear-positive or culture-positive TB

ā€‹ARPE = Aggregate Reports on Performance Evaluation ā€“ Contact Investigation

ā€‹NAAT = nucleic acid amplification test

ā€‹EDN = Electronic Disease Notification system  

ā€‹ RVCT = Report of Verified Case of Tuberculosis

ā€‹HIV = human immunodeficiency virus       

ā€‹ TB = tuberculosis

ā€‹LTBI = latent tuberculosis infection           ā€‹

ā€‹ US = United Statesā€‹

ā€‹
Page Last Updated :